Alimera makes deal with Emory

Article

Alimera Sciences has entered into an exclusive worldwide agreement with Emory University, USA to explore oxidative stress management as a treatment for ophthalmic diseases.

Alimera Sciences has entered into an exclusive worldwide agreement with Emory University, USA to explore oxidative stress management as a treatment for ophthalmic diseases.

The agreement gives Alimera the exclusive option to license a unique class of compounds, NADPH (nicotinamide adenine dinucleotide phosphate reduced form) oxidise inhibitors, as a potential treatment for conditions such as dry age-related macular degeneration (AMD).

Alimera will also receive the exclusive rights to sublicense in ophthalmology and the exclusive rights for non-ophthalmic use. The company will be responsible for the development and commercialization of the compounds and Emory will receive milestone payments and royalties from net sales.

Recent Videos
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Brent Kramer, MD, of Vance Thompson Vision speaks at the 2024 AAO meeting
© 2024 MJH Life Sciences

All rights reserved.